Disease model based on activation of unfolded protein response.
Gba1aMB02296 mutant adults do not show any decrease in their climbing ability relative to age-matched controls and their survival rate under low-nutrient condition as well as sleep pattern is also comparable to wild-type.
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has short lived phenotype
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has abnormal neuroanatomy | adult stage | progressive phenotype
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has decreased cell number | adult stage | progressive phenotype
CG31148[+]/Gba1aMB02296, Gba1bMB03039 has abnormal locomotor behavior phenotype
CG31148[+]/Gba1aMB02296, Gba1bMB03039 has some die during third instar larval stage phenotype
CG31148[+]/Gba1aMB02296, Gba1bMB03039 has some die during pupal stage phenotype
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has dopaminergic PPM2 neuron | adult stage | progressive phenotype
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has dopaminergic neuron | adult stage | progressive phenotype
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has dopaminergic PPL1 neuron | adult stage | progressive phenotype
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has dopaminergic PPM1 neuron | adult stage | progressive phenotype
Gba1aMB02296, Gba1b[+]/Gba1bMB03039 has dopaminergic PPM3 neuron | adult stage | progressive phenotype
Gba1aMB02296, Gba1bMB03039 double heterozygotes show a progressive decrease in the number of adult dopaminergic neurons (total neurons and PPL1, PPM1/2 and PPM3 cluster neurons), as it is observed at day 22, but not at days 2 and 12, post eclosion, as compared to controls.
CG31414MB03039/+, CG31148MB02296/+ double heterozygotes show a significant decrease in survival from L3 larva to pupa and again from pupa to adult, compared to controls.
CG31414MB03039/+, CG31148MB02296/+ double heterozygotes show significant locomotion dysfunction (measured in a climbing assay) at 22 days of age, compared to controls.